Calidi Biotherapeutics Inc.
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Calidi Biotherapeutics Inc. Company Information, Fundamentals, and Technical Indicators
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Calidi Biotherapeutics Inc. In Our Stock Scanner
As of Apr 14, 2026Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.